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Objectives: Limited treatment options available for Mycobacterium abscessus infections include the parenteral
b-lactam antibiotics cefoxitin and imipenem, which show moderate in vitro activity. Other b-lactam antibiotics
(except meropenem) have no considerable in vitro activity, due to their rapid hydrolysis by a broad-spectrum
b-lactamase (Bla_Mab). We here addressed the impact of b-lactamase production and b-lactam in vitro stability
on M. abscessus MIC results and determined the epidemiological cut-off (ECOFF) values of cefoxitin, imipenem
andmeropenem.
Methods: By LC high-resolution MS (LC-HRMS), we assessed the in vitro stability of cefoxitin, imipenemandmero-
penem.M. abscessus ATCC 19977 strain and its isogenic blaMab deletionmutant were used for MIC testing. Based
on MIC distributions for M. abscessus clinical strains, we determined ECOFFs of cefoxitin, imipenem and
meropenem.
Results: A functional Bla_Mab increased MICs of penicillins, ceftriaxone and meropenem. LC-HRMS data showed
significant degradation of cefoxitin, imipenemandmeropenemduring standard antibiotic susceptibility testing pro-
cedures. MIC, MIC50 and ECOFF values of cefoxitin, imipenemandmeropenemare influenced by incubation time.
Conclusions: The results of our study support administration of imipenem, meropenem and cefoxitin, for treat-
ment of patients infected with M. abscessus. Our findings on in vitro instability of imipenem, meropenem and
cefoxitin explain the problematic correlation between in vitro susceptibility and in vivo activity of these antibiotics
and question the clinical utility of susceptibility testing of these chemotherapeutic agents.
Introduction
Mycobacterium abscessus is a dreadful and arduous to treatmyco-
bacterial pathogen with a high level of innate resistance to most
commercially available antibiotics, including the antituberculous
agents.1–5 Clinically relevant cases are predominantly associated
with pulmonary infections in patients with cystic fibrosis or bron-
chiectasis anddisseminateddisease in immunocompromised indi-
viduals.2–4M. abscessus is also highly resistant to disinfectants and
therefore it ordinarily causes skin and soft tissue infections follow-
ing plastic surgery, tattooing or body piercing.3,5–8 Several
healthcare-associated outbreaks of M. abscessus infections, that
have been reported worldwide, highlight the increasing medical
importance of this MDR pathogen and the urgent need for reliable
medication strategies.3,4,9
As M. abscessus clinical isolates are uniformly resistant to
standard chemotherapeutic agents, so far, no reliable antibiotic
regimen for M. abscessus pulmonary infections has been
established. Antibiotic administration is empirical and heavily
relies on in vitro antibiotic susceptibility testing (AST) by broth
microdilution and definitive subspecies identification.3,10
The clinical importance of M. abscessus subspecies identification
(M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and
M. abscessus subsp. massiliense) is attributed to the fact
that M. abscessus subsp. abscessus and M. abscessus subsp. bol-
letii have a functional inducible erythromycin ribosome
methyltransferase gene [erm(41)], which confers macrolide re-
sistance, whereas M. abscessus subsp. massiliense has a non-
functional erm(41), leading to macrolide susceptibility, and thus
M. abscessus subsp.massiliense infections have more favourable
prognosis and treatment outcomes.10–18 The American Thoracic
Society recommends for the treatment of M. abscessus lung in-
fections a combination therapy of an oral macrolide (clarithro-
mycin or azithromycin) for clinical isolates susceptible to
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macrolides and the intravenous aminoglycoside drug amikacin,
administered together with a parenteral b-lactam antibiotic,
cefoxitin or imipenem.3,19–21 However, with the exception of the
macrolide class, very limited data are present in the literature
concerning the correlation between AST and the clinical efficacy
of these recommended antimycobacterial drugs.22 The clinical
relevance of AST remains a controversy, particularly on account
of technical problems associated with AST methods, reproduci-
bility of AST results, significant discrepancies between in vitro
susceptibility and in vivo activity of a given drug and solubility
and stability issues of the drugs used.23 Ideally, clinicians could
take advantage of AST forM. abscessus, when the in vitro suscep-
tibility to a drug is consistent with a clinically achievable drug ex-
posure in vivo, resulting in favourable treatment outcomes.
Accordingly, clinical susceptibility breakpoints must represent
MIC distributions and zone diameter distributions for WT and re-
sistant strains, resistance mechanisms, dosing regimens, drug
pharmacokinetics, pharmacodynamics and epidemiological cut-
off (ECOFF) values and must allow prediction of treatment out-
comes.22–25 CLSI is the only organization worldwide that has
published AST guidelines for rapid growing mycobacteria24
recommending susceptibility testing of amikacin, cefoxitin, cipro-
floxacin, clarithromycin, doxycycline or minocycline, imipenem,
linezolid, moxifloxacin, trimethoprim/sulfamethoxazole and
tobramycin.25 The breakpoint concentrations for these antibi-
otics have nonetheless been set on the basis of in vitro driven
studies and their efficacy (except the new drugs linezolid and
tigecycline) has been clinically evaluated by Wallace et al.26
principally in patients with extrapulmonary disease. To date,
EUCAST has not officially announced guiding principles for non-
tuberculousmycobacteria susceptibility testing.
Frequently used therapeutics for M. abscessus infections are
the parenteral b-lactam antibiotics cefoxitin and imipenem,24
which have moderate in vitro activity, with MIC values reported
by Dubée et al.27 forM. abscessus subsp. abscessus CIP 104536 of
32 and 8mg/L, respectively. Meropenem, an ultra-broad-
spectrum carbapenem closely related to imipenem,28 displayed
a lower MIC value (16mg/L) than cefoxitin for M. abscessus
subsp. abscessus CIP 104536.27 Most of the other b-lactam anti-
biotics have no considerable in vitro activity due to their rapid hy-
drolysis by a broad-spectrum class A b-lactamase, encoded by
MAB_2875, namely Bla_Mab, which was reported as the major
determinant of b-lactam resistance in M. abscessus.27,29
Determination of the kinetic parameters of this enzyme revealed
that it can slowly hydrolyse imipenem and meropenem, while
cefoxitin hydrolysis by Bla_Mab is immensely slow, as the
methoxy group at cefoxitin’s b-lactam ring was predicted to
block the activity of class A b-lactamases.27,29,30
As imipenem,meropenemand cefoxitin are known tohave lim-
ited in vitro stability,31 we assessed by LC high-resolution MS
(LC-HRMS) the in vitro stability of these b-lactams and, by exploit-
ing a blaMab deletionmutant that we generated, we addressed the
biological effect of b-lactam stability and b-lactamase production
on MIC testing results after different periods of incubation. The dir-
ect impact of b-lactam stability on AST testing was further
addressed by MIC determination of fresh and pre-incubated
b-lactam antibiotics for the ampicillin-susceptible Escherichia coli
XL1-Blue MRF0 strain. What is more, based on MIC distributions for
M. abscessus clinical strains, mainly isolated from respiratory
samples, we estimated ECOFFs of cefoxitin, imipenem and mero-
penem. Our results show that MIC, MIC50 and ECOFF values of
cefoxitin, imipenem and meropenem are severely influenced by
stability issues, thus questioning the clinical utility of AST of cefox-
itin, imipenem and meropenem, but not the use of these antibi-
otics in patientswithM. abscessus infections.
Materials and methods
Bacterial strains and growing conditions
(i) E. coli strains were cultivated in LB medium or on LB agar plates, when
necessary, containing either ampicillin (120mg/L) or apramycin (50mg/L),
at 37 C, overnight. For E. coli MIC testing and all cloning steps when con-
structing the blaMab deletion vector pSE-katG-aac(3)IV-DMAB_2875, E. coli
XL1-Blue MRF0 (Stratagene, Switzerland) was used. (ii) M. abscessus strains
were grown in Middlebrook 7H9-OADC-Tween 80 liquid medium or on LB
agar plates, when needed, containing either apramycin (50mg/L) or isonia-
zid (32mg/L), at 37 C, for 5days. TheM. abscessus ATCC 19977 type strain,
theM. abscessusDblaMabmutant strain and 62 clinical isolates ofM. absces-
sus (33 M. abscessus subsp. abscessus, 17 M. abscessus subsp. bolletii and
12 M. abscessus subsp. massiliense isolates) were used throughout this
study. The M. abscessus clinical isolates were mainly isolated from respira-
tory samples that were received at the Swiss National Center for
Mycobacteriawithin the years 2007–14.
Definitive subspecies identification of clinical isolates
Subspecies identification of M. abscessus isolates (M. abscessus subsp.
abscessus,M. abscessus subsp. bolletii andM. abscessus subsp.massiliense)
was based on the 16S rRNA, rpoB and erm(41) gene sequences.12–14,32,33
Subspecies attribution forM. abscessus complex isolateswas performed ac-
cording to Tortoli et al.12 The obtained sequences were analysed with the
use of Lasergene SeqMan software (DNASTAR, USA), the SmartGene IDNS
mycobacteria and rpoB databases (SmartGene, Switzerland), and the
BLAST algorithm (http://blast.ncbi.nlm.nih.gov).
Antibiotics
Imipenem, meropenem, cefoxitin, ceftriaxone, ceftazidime, penicillin G,
ampicillin, amoxicillin, amikacin, apramycin and isoniazid were bought
from Sigma–Aldrich, Switzerland. All compounds were dissolved in H2O, ac-
cording to themanufacturer’s recommendations, filter sterilized, aliquoted
into stock solutions of 3–50g/L and finally stored at#20 C.
Deletion of MAB_2875 in M. abscessus
A 1.4kbp HpaI/Pfl23II fragment from position 2926650 to 2928011
(50blaMab flanking sequence) and a 1.5kbp Pfl23II/Pfl23II fragment from
position 2928642 to 2930147 (30blaMab flanking sequence) were PCR ampli-
fied using genomic DNA from M. abscessus ATCC 19977 (50-GAAT
TAGTTAACCAGGTGTGATCCAGATGCCCG-30, 50-GAATTTCGTACGGGCCGCCGAAA
TCCTTTTCC-30 and 50-GAAATACGTACGCCATCGTGATGGCGGTACTCAC-30, 50-GA
ATTTCGTACGGTGTCTACCAGTCCTTGCACACC-30, respectively) and cloned into
the pSE-katG-aac(3)IV vector with corresponding enzymes, resulting in the
blaMab deletion vector pSE-katG-aac(3)IV-DMAB_2875. M. abscessus blaMab
deletion mutant was generated using a double selection strategy described
previously in detail by Rominski et al.34,35 In brief, pSE-katG-aac(3)IV-
DMAB_2875 was transformed into electrocompetent M. abscessus ATCC
19977. Competent cells (100lL) were mixed with 1–2lg of plasmid DNA
(supercoiled) and electroporated in a Bio-Rad Gene pulser II using 4mmgap
electroporation cuvettes and the settings: 2.5kV, 1000X and 25lF.36 Cells
were resuspended after electroporation in 0.9mL of 7H9-OADC-Tween 80 li-
quidmedium and incubated for 5h at 37 C. Proper dilutions were eventually
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plated on selective agar and, after 5days of incubation, single colonies were
picked and restreaked on LB agar plates with appropriate antibiotics.
Transformants were selected on LB agar plates containing apramycin and
identified by aac(3)IV colony PCR (primers: 50-CACCTTCTTCACGAGG
CAGACCTC-30 and50-GGTCTGACGCTCATGGAACTAGTAGG-30). Isolation of gen-
omic DNA was performed by phenol-chloroform-isoamyl alcohol extraction
as describedpreviously37and single crossover transformantswere confirmed
by Southern blot analysis with a 0.45kbp SacI 30blaMab DNA probe and sub-
jected to counterselection on LB agar plates containing isoniazid. Single colo-
nies were screened for deletion of MAB_2875 by PCR (primers:
50-GTACACCGTCTTCGGGACG-30 and 50-GAAAGTGCGAGTACGCGTCTG-30) and
their genotype was finally verified by Southern blot analysis using the same
0.45kbp SacI 30blaMab DNA probe. In this way, a 0.63kbp region of the
MAB_2875wasdeleted fromthegenomeofM. abscessusATCC19977.
Nitrocefin test
For the detection of b-lactamase production in the M. abscessus ATCC
19977 type strain and the DblaMab mutant strain we performed a chromo-
genic nitrocefin test (BectonDickinson, USA). Tubes containing (i) pure nitro-
cefin solution, (ii) nitrocefin solution inoculated with five colonies of the
M. abscessus ATCC 19977 type strain and (iii) nitrocefin solution inoculated
with five colonies of the M. abscessus DblaMab mutant were incubated for
1h at room temperature before a photowas taken.
MIC assays
MIC assays were performed with the microdilution method and according
to CLSI guidelines,25 but with incubation of the 96-well microtitre plates at
37 C, as described previously.34,35Directly after the preparation of the anti-
biotic stock solutions, working solutions were prepared by diluting the cor-
responding stock solutions in CAMHB (pH 7.4) (Becton Dickinson,
Switzerland) to a concentration of 512mg/L (final antibiotic concentration
used for AST; 256mg/L) and were subsequently stored at #80 C. Shortly
before the conduct of an MIC experiment (day 0), working solutions were
thawed for the first timeandweredirectly used. Alternatively, working solu-
tions were thawed and pre-incubated for 1–7days at 37 C and their inhibi-
tory effect was compared with freshly thawed antibiotics. Two-fold serial
dilutions of the freshly thawed (and pre-incubated: for the pre-incubation
MIC experiments) working solutions were prepared using CAMHB in sterile
96-well microtitre plates (Greiner Bio-One, Switzerland). Each 96-well
microtitre plate included a positive growth control lacking antibiotic and a
sterile negative control containing only CAMHB. To achieve a final inoculum
titre of 1–5%105 cfu/mL, while final volume per well was 100lL, bacterial
suspensions of strains with smooth or rough phenotypes were adjusted to
aMcFarland standard of 0.5 and 3.0, respectively, and subsequently diluted
in CAMHB. The proper titre of the inocula was confirmed by obtaining cfu
counts on LB agar plates. MIC values were assessed by visual inspection
after incubation at 37 C for 16h for E. coli strains and 3, 5, 7 and 12days
for M. abscessus. MIC assays for E. coli, M. abscessus ATCC 19977 and the
M. abscessus blaMab deletion mutant were conducted in triplicate. MIC
assays forM. abscessus complex clinical isolateswere performed once.
LC-HRMS assays
In vitro antimicrobial stability of cefoxitin, imipenem and meropenem was
evaluated using CAMHB and the maximum final antibiotic concentration
used for AST (256mg/L). A different test tube was prepared for each antibi-
otic and for every reading timepoint, i.e. 3, 5, 7 and 12days. A day 0 control
was used to define the 100% relative antibiotic concentration. The antibi-
otic-containing test tubes were incubated under the same temperature
conditions as themicrotitre plates used for AST (37 C). Cefoxitin, imipenem
andmeropenemwere quantified by LC-HRMS on aQ Exactive hybrid instru-
ment (Thermo Fisher, Switzerland). Samples were precipitated using a
precipitation solution consisting of methanol/acetonitrile (80/20, v/v),
containing the corresponding stable-isotope labelled internal standards.
After centrifugation at 11700g for 10min at 4 C, 10lL of the clear super-
natant was injected into the turbulent flow online extraction system.
As extraction column a Cyclone column (50%0.5mm) was used and for
analytical chromatography a Hypersil Gold C8 column (100%3mm) was
used. Mobile phases consisted of 10mM ammonium acetate in water-
!0.1% formic acid and 10mM ammonium acetate in methanol/acetoni-
trile (50/50, v/v)!0.1% formic acid. Samples were analysed in positive
heated electrospray ionization mode and detection was done in full-scan
mode with a resolution of 70000 full width at half maximum (calculated
form/z 200).
ECOFF determination
MIC data for 62 M. abscessus complex clinical isolates were collected and
the resistance population analysis charts were calculated using the inte-
grated histographical analysis tool of Microsoft Excel. Median MIC50 values
of cefoxitin, imipenem and meropenem for the M. abscessus complex clin-
ical strains were calculated using SPSS software. All ECOFF values were
determined by the eyeballmethod.38,39
Results and discussion
Generation of the M. abscessus MAB_2875 deletion mutant
Similarly to our previously published techniques,34,35 we intended to
generate anM. abscessus DMAB_2875mutant, which would enable
us to address directly the role of the b-lactamase production of
M. abscessus on MIC testing results of b-lactam antibiotics.
The blaMab deletion mutant was constructed by transformation of
M. abscessus ATCC 19977 with plasmid pSE-katG-aac(3)IV-
DMAB_2875 applying an apramycin-positive selection40 and a katG-
dependent isoniazid counterselection strategy (Figure 1a).34,35
Deletion of MAB_2875 was confirmed by Southern blot analysis
(Figure 1b). While this study was ongoing, a DMAB_2875 mutant
was also generated byDubée et al.,27 butwith different cloning, gen-
eticmanipulation and selection strategies.
M. abscessus blaMab deletion mutant is deficient in
b-lactamase production
To assess the b-lactamase production of theM. abscessus DblaMab
mutant,weperformeda chromogenic nitrocefin test. The cephalo-
sporin nitrocefin changes colour from yellow to red in the presence
of b-lactamases that hydrolyse the amide bond in its b-lactam
ring.41 As Figure 2 shows, the tube containing yellow pure nitroce-
fin solution (Figure 2a) did not change colour. The tube containing
nitrocefin solution inoculated with M. abscessus ATCC 19977
(Figure 2b) changed colour and became red, while the tube con-
taining nitrocefin solution inoculated with the M. abscessus
DblaMab mutant (Figure 2c) stayed yellow, confirming that the
M. abscessus blaMab deletion mutant is deficient in b-lactamase
production. These results align with the findings from Dubée
et al.,27 who reported Bla_Mab as the single determinant of b-lac-
tam resistance inM. abscessus.
AST of M. abscessus DMAB_2875
To explore the role of Bla_Mab inM. abscessus b-lactam resistance,
MIC values for the M. abscessus ATCC 19977 type strain and the
M. abscessus DblaMab mutant were determined with the
microdilution method for the b-lactam antibiotics, imipenem,
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meropenem, cefoxitin, ceftriaxone, ceftazidime, penicillin G, ampi-
cillin and amoxicillin, and a control antibiotic from the class of ami-
noglycosides, i.e. amikacin (Table 1). As formerly reported,27
M. abscessus ATCC 19977 was highly resistant to all b-lactam
antibiotics tested except imipenem, meropenem and cefoxitin.
Deletion of blaMab significantly reduced the MIC values of all peni-
cillins tested (penicillin G, ampicillin and amoxicillin) and the
cephalosporin ceftriaxone. MIC values of 256mg/L of the
oxyimino-cephalosporin ceftazidime for both M. abscessus ATCC
19977 and the M. abscessus DblaMab mutant suggest that ceftazi-
dime is not active against M. abscessus. Cefoxitin MIC values of
32mg/L (day 3) for bothM. abscessus ATCC 19977 and theDblaMab
mutant (Table 1) agree with earlier reported data,27 corroborating
previous molecular modelling and structural analyses,42 which
delineated that substitutions of the b-lactam ring by a methoxy
group in cefoxitin inhibits the activity of class A b-lactamases.30 As
expected, amikacinMICswere independent of the bla genotype.
To date, none of the recent studies on b-lactam susceptibility
testing of M. abscessus CIP 104536 and the M. abscessus DblaMab
mutant has reported MIC data obtained after 3days of incuba-
tion.27,29,30,43,44 Indeed, CLSI guidelines25 for imipenemMIC testing
for rapid growing mycobacteria recommends a maximum incuba-
tion period of 3days and state that ‘the reported breakpoints for
imipenem are considered tentative’. Our observation that imi-
penem, meropenem and cefoxitin MIC values rise substantially
with the incubation time for both the M. abscessus ATCC 19977
strain and theM. abscessus DblaMabmutant (Table 1), in correlation
with the fact that certain antibiotics undergo partial degradation
Figure 1. Genotypic analyses of the M. abscessus blaMab locus. (a) Schematic drawing of genotypes and recombination events. (b) Southern blot ana-
lysis confirmed the deletion of MAB_2875 from the genome of M. abscessus. Genomic DNA of M. abscessus ATCC 19977 (1) and M. abscessus trans-
formant with pSE-katG-aac(3)IV-DMAB_2875 targeting vector after KatG-dependent isoniazid counterselection (2) was digested with SacI and
probed with a 0.45 kbp fragment from the 30 blaMab flanking region. Based on M. abscessus genome annotation and vector sequence, the pattern is
consistent with hybridization to a 4.0 kbp fragment of the WT parental strain and to a 3.4 kbp fragment of theM. abscessus DblaMab mutant (D).
(a) (b) (c)
NCF NCF + M. abscessus
ATCC 19977
NCF + M. abscessus
ΔblaMab
Figure 2. Chromogenic nitrocefin solution test results after incubation
for 1 h at 37 C. (a) Tube containing pure nitrocefin solution. (b) Tube con-
taining nitrocefin solution inoculated with M. abscessus ATCC 19977WT.
(c) Tube containing nitrocefin solution inoculated with the M. abscessus
DblaMab mutant. NCF, nitrocefin. This figure appears in colour in the on-
line version of JAC and in black and white in the print version of JAC.
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under in vitro testing conditions,45 led us to investigate further the
effect of the b-lactamstability onMIC testing procedures.
Effect of b-lactam stability on E. coli MIC testing
To determine experimentally whether the results of the
M. abscessusMIC testing of b-lactams after 3, 5 and 7days of incu-
bation clearly reflect b-lactamase production or are affected by
instability of the antibiotics tested, we performed an MIC experi-
ment using the E. coli XL1-Blue model strain, which produces no
b-lactamases, and fresh and pre-incubated (at 37 C, for 1–7days)
b-lactam antibiotics. In that way, all MIC results could be obtained
after 16h of incubation of the microtitre plates and putative MIC
differences between the fresh and the pre-incubated antibiotics
could be directly correlated to instability of the tested antibiotics.
Our results show that pre-incubation at 37 C affects MIC results of
imipenem, meropenem and to a lesser extent cefoxitin and cef-
tazidime (Figure 3a and b), whereas the MIC results of ceftriaxone,
penicillin G, ampicillin, amoxicillin and as expected the control sta-
ble aminoglycoside antibiotic amikacin are not influenced by pre-
incubation (Figure 3b, c and d). By assuming that drug degradation
follows an exponential decay process and using the data displayed
in Figure 3, we calculated the half-life values of imipenem as
0.75days, of meropenem as 1.5days and of cefoxitin as 3days.
We therefore conclude that the increased MIC values of the pre-
incubated antibiotics, already before day 3, reflect instability of the
antibiotics. Reading ofM. abscessusMICs at day 3 and later gives a
de factomisleading impression for the true extent of activity of imi-
penem,meropenemand cefoxitin.
In vitro antimicrobial stability of cefoxitin, imipenem
and meropenem by LC-HRMS
Based on our results suggesting that incubation of cefoxitin, imi-
penem and meropenem at 37 C gives rise to misleading MIC




M. abscessus ATCC 19977 M. abscessus DblaMab
day 3 day 5 day 7 day 12 day 3 day 5 day 7 day 12
Imipenem 2 4 8 64 1 2 4 64
Meropenem 8 16 32 256 2 4 4 16
Cefoxitin 32 32 64 128 32 32 32 128
Ceftriaxone 64 64 64 64 8 16 16 16
Ceftazidime .256 .256 .256 .256 256 .256 .256 .256
Penicillin G .256 .256 .256 .256 2 4 4 4
Ampicillin .256 .256 .256 .256 4 4 8 8
Amoxicillin .256 .256 .256 .256 2 4 4 4
Amikacin 1 2 4 8 1 2 4 8
Carbapenems(a) (b)
(c) (d)
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Figure 3. MIC values for E. coli XL1-Blue strain of fresh and pre-incubated (at 37 C, for 1–7days) b-lactam antibiotics. (a) Carbapenems: imipenem




results, we intended to address the in vitro stability of these
b-lactams, by quantifying them using LC-HRMS. Tubes containing
CAMHB and the maximum antibiotic concentration used for AST
(256mg/L) were incubated at 37 C. The 100% relative antibiotic
concentration of each antibiotic was defined by a day 0 control
tube. On days 3, 5, 7 and 12 the concentrations of cefoxitin, imi-
penem and meropenem were quantified. Data obtained by the
LC-HRMSmethod, clearly showdegradation of cefoxitin, imipenem
and meropenem. Particularly, the relative concentration on day 3
for imipenem dramatically dropped to 3.3%, whereas for cefoxitin
and meropenem it dropped to 36.6% and 35.6%, respectively
(Figure 4e, j and o). By using the results of this assay, the calculated
half-life of imipenemwas 0.6days, that ofmeropenemwas 2days
and that of cefoxitin was 2.1days. These findings agree with those
deducted from the E. coliMIC testing and confirm that theMIC val-
ues of cefoxitin, imipenem and meropenem for M. abscessus on
day 3 and later aremisleading, as concentration of the active com-
pound is lowered. Particularly for imipenem, MIC50 on day 3 was
16mg/L (Figure 4j). However, growth inhibition of half of the clin-
ical isolates was in reality achieved by considerably lower drug
amounts, as the true active relative concentration of imipenem
shrank to 3.3% by day 3 due to the short half-life of this antibiotic.
Consequently, due to instability of imipenem, meropenem and
cefoxitin, M. abscessus MIC determination after 3days of incuba-
tion does not reflect the potency of these three compounds, par-
ticularly as clinical administration3 of these drugs is daily and in
multiple doses. These data, on the one hand, question the utility of
susceptibility testing of imipenem, meropenem and cefoxitin, but,
on the other hand, support administration of these parenteral
b-lactam antibiotics as part of combinational regimens for the
treatment ofM. abscessus infections.
ECOFF values of cefoxitin, imipenem and meropenem for
M. abscessus complex
According to EUCAST, for the determination of clinical suscepti-
bility breakpoint values and improvement of the MIC interpret-
ation for clinical isolates, ECOFFs need to be defined to separate
the WT population from any non-WT strains with acquired drug
resistancemechanisms to the chemotherapeutic agents in ques-
tion.46 We therefore endeavoured to estimate ECOFF values of
cefoxitin, imipenem and meropenem by visual inspection of the
MIC histographic distribution analysis (eyeball method)36,37 for
62M. abscessus complex clinical strains isolated from respiratory
samples, after 3, 5, 7 and 12days of incubation at 37 C
(Figure 4). The results show that MIC distributions for our collec-
tion of M. abscessus complex isolates of cefoxitin, imipenem and
meropenem are close to the breakpoints established by CLSI and
that the eyeball-estimated ECOFF values did not show a separ-
ation of the M. abscessus complex isolates into two distinct sub-
groups, WT and resistotype. ECOFFs were set at the highest MIC
value observed among the isolates tested and all of these iso-
lates are therefore classified in the WT subgroup. According to
this classification, a putative clinical isolate with an additional
b-lactam resistance mechanism would have a very high MIC
value (higher than the corresponding ECOFF) that would be nei-
ther detected by standard AST laboratory procedures nor rele-
vant for clinical interpretation. Interestingly, the presence or
absence of a functional or non-functional b-lactamase in
M. abscessus could not be predicted by the MIC distribution
for the clinical isolates, as the MIC values determined for
M. abscessus DblaMab (Table 1) fall in the MIC distribution for the
‘WT’ subgroup of clinical isolates of all three b-lactams (Figure 4).
Furthermore, our results show that MIC and MIC50 values of
cefoxitin, imipenem and meropenem are greatly influenced by in-
cubation time; the longer the incubation period, the higher the MIC
for the individual strains, the MIC50 and the estimated ECOFF val-
ues (Figure 4). The presented MIC distribution bars, as well as the
MIC50 and ECOFF lines, would represent valid data for MIC, MIC50
and ECOFF values, only if the drugs were 100% stable. However,
according to the LC-HRMS results, cefoxitin, meropenem and par-
ticularly imipenemwere proven as unstable compounds and thus
MIC values for the M. abscessus complex clinical isolates of these
three b-lactams on day 3 and later are certainly overestimated, as
already discussed. If the concentration of the biological active
form of the drug could have been kept constant during the AST
procedures, we expect that the position of the MIC distribution
bars and MIC50 and ECOFF lines would be shifted to the left in all
MIC distribution analysis graphs (Figure 4). Our observations high-
light the impact of cefoxitin, imipenem and meropenem stability
issues on MIC, MIC50 and ECOFF determination for M. abscessus
complex clinical isolates.
Conclusions
Taken together, our study confirmed Bla_Mab as the major deter-
minant of innate b-lactam resistance in M. abscessus and ad-
dressed experimentally the biological effect of b-lactamase
production and b-lactam stability on M. abscessus MIC testing re-
sults after different incubation periods. Our results show that MIC,
MIC50 and ECOFF values of cefoxitin, imipenem and meropenem
are immensely influenced by incubation time. LC-HRMS data and
MIC determination of pre-incubated drugs for the fast growing
model organism (E. coli) proved significant degradation of cefox-
itin, imipenem and meropenem during standard AST procedures,
explaining the problematic correlation between in vitro susceptibil-
ity of these three b-lactams and their in vivo activity. Our findings
critically question the clinical utility of cefoxitin, imipenem and
meropenem susceptibility testing, but further support administra-
tion of these chemotherapeutic agents for the treatment of
M. abscessus infections.
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Figure 4. MIC distributions of cefoxitin (a–d), imipenem (f–i) and meropenem (k–n) for M. abscessus complex strains (n"62). MIC50 values are indi-
cated by a black vertical continuous line, whereas ECOFF values are indicated by a black vertical broken line. *, MIC values for the M. abscessus ATCC
19977 type strain; D, MIC values for the M. abscessus DblaMab mutant. Drug stability of cefoxitin (e), imipenem (j) and meropenem (o) in comparison
with median MIC50 values. (e, j and o) Crosses connected with a black continuous line show relative drug concentrations and filled circles connected
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